Clinical Trial Results:
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on
progression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy.
Summary
|
|
EudraCT number |
2008-001736-12 |
Trial protocol |
BE ES AT DE IE IT FR GB |
Global completion date |
14 Jun 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Jul 2016
|
First version publication date |
12 Jun 2015
|
Other versions |
|
Summary report(s) |
NO21160_CSR synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.